Melanotan II Research Overview

Melanotan II (MT‑II) is a synthetic cyclic peptide analog of alpha-melanocyte-stimulating hormone (α-MSH). It has been investigated in laboratory and preclinical studies to explore melanocortin receptor signaling pathways and neuroendocrine regulation (Hadley & Dorr, 2006). MT‑II interacts with multiple melanocortin receptor subtypes, making it a tool compound for research into pigmentation biology, appetite signaling, and central melanocortin system function (Cone, 2005).

MT‑II is chemically stabilized relative to endogenous α-MSH, allowing prolonged receptor engagement in vitro and in animal models (Hadley & Dorr, 2006). Preclinical research often employs MT‑II to probe structure–activity relationships among melanocortin receptor subtypes, without implying therapeutic effects.

Molecular Formula: C₅₀H₆₉N₁₅O₉ (Wikipedia, 2025)

---

Mechanism of Action in Laboratory Models

Melanotan II functions primarily as a non-selective agonist of melanocortin receptors, which are part of the G protein–coupled receptor (GPCR) family:

• MC1R – MT‑II has been studied for receptor engagement in melanocytes, where α-MSH pathways regulate melanin synthesis (Cone, 2005).

• MC3R and MC4R – In rodent models, MT‑II has been investigated for effects on feeding behavior and hypothalamic appetite signaling (Weninger et al., 2003).

• Multi-receptor engagement – MT‑II binds several melanocortin receptor subtypes (MC1R, MC3R, MC4R, MC5R) and is used to explore receptor selectivity and intracellular signaling cascades in vitro (Hadley & Dorr, 2006).

Laboratory studies typically monitor intracellular second messengers (e.g., cAMP) or gene expression changes downstream of receptor activation to evaluate MT‑II’s effects.

---

Primary Research Findings

Research with MT‑II spans preclinical pharmacology, in vitro assays, and animal behavior models:

• Receptor Pharmacology – The cyclic peptide structure enhances stability and receptor affinity compared with linear α-MSH fragments, supporting prolonged melanocortin receptor engagement (Hadley & Dorr, 2006).

• Pigmentation Biology – MT‑II has been investigated for MC1R-mediated melanin synthesis in melanocyte cultures and rodent models, enabling study of melanogenic pathways independently of UV exposure (Cone, 2005).

• Appetite Regulation – In rodent studies, MT‑II administration to the nucleus accumbens or hypothalamus has been shown to reduce food intake and alter motivated feeding behavior, providing insight into central melanocortin control of energy balance (Weninger et al., 2003).

• Neurobiology – MT‑II has been explored in peripheral nerve injury models for potential neurotrophic signaling effects, including observations of neuronal survival and functional recovery in rodents (Hadley & Dorr, 2006).

• Sexual Behavior Research – MT‑II has been used in human experimental contexts to examine melanocortin-mediated sexual arousal pathways, primarily for mechanistic understanding rather than therapeutic assessment (Hadley & Dorr, 2006).

---

System-Specific Research Applications

Pigmentation and Melanocyte Biology

Laboratory research often investigates:

• MC1R receptor activation and downstream melanogenic enzyme expression

• Melanin production pathways in melanocyte cultures

• Effects on melanocyte signaling independent of environmental UV exposure (Cone, 2005)

Appetite and Energy Regulation

Preclinical feeding models explore:

• Hypothalamic and accumbens melanocortin receptor pathways

• POMC-derived peptide interactions and downstream appetite signaling (Weninger et al., 2003)

Neurobiology and Peripheral Nerve Research

Research investigations include:

• Neuronal survival signaling in peripheral nerve injury models

• Melanocortin receptor involvement in tissue-level neurotrophic pathways (Hadley & Dorr, 2006)

---

Comparative Research Context

MT‑II is commonly studied alongside Melanotan I (afamelanotide) and other α-MSH analogs to investigate receptor subtype selectivity, ligand stability, and intracellular signaling differences (Hadley & Dorr, 2006). Comparative studies are presented in a mechanistic research context, without suggesting superior efficacy or clinical benefits.

---

Research Handling and Format

• Lyophilized Powder – MT‑II is typically supplied as freeze-dried powder, which supports stability, accurate dosing in vitro, and reproducibility in experimental protocols.

• Storage Recommendations – Store in a cool, dry environment and protect from light and moisture. Follow standard laboratory safety protocols.

• Experimental Preparation – Reconstitution is done under controlled conditions; stability post-reconstitution may vary and should be considered in experimental planning.

---

Research Use Only Disclaimer

This compound is intended solely for laboratory research purposes. It is not for human consumption, clinical use, therapeutic application, or veterinary use. Investigators must comply with all institutional and regulatory guidelines when handling synthetic research peptides.

---

References

• Cone, R. D. (2005). Anatomy and regulation of the central melanocortin system. Nature Reviews Drug Discovery, 4(10), 921–930. https://doi.org/10.1038/nrd1848

• Hadley, M. E., & Dorr, R. T. (2006). Melanocortin peptide therapeutics: historical milestones and preclinical studies. Pharmacology & Therapeutics, 109(3), 295–308. https://doi.org/10.1016/j.pharmthera.2005.07.008

• Weninger, S. C., et al. (2003). Control of feeding behavior by melanocortin receptors in the nucleus accumbens. Journal of Neuroscience, 23(27), 8890–8898. https://doi.org/10.1523/JNEUROSCI.23-27-08890.2003

• Wikipedia contributors. (2025). Melanotan II. Wikipedia. https://en.wikipedia.org/wiki/Melanotan_II

---